Awareness: The PCCN-Toronto and Side by Side Prostate Cancer Support Groups Newsletter. In this Issue: 2013 Father’s Day Walk/Run Totals Dr. Danny Vesprini and Ken Shaw – Sept. 2013 Dr. Robert Hamilton– July 2013 Our redesigned website Toronto Warriors Survivor Forum 2014 A message from our out-going chairman A message from our in-coming chairman Read it by clicking the link below to open the pdf file: November_Newsletter_2013
Men (aged 40-49 years) with a single baseline PSA below 1.0 have a very low long-term risk of prostate cancer
Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: Results from a prospectively screened population cohort – Abstract [www.urotoday.com] Published on 19 November 2013 OBJECTIVE: To study the use of a baseline prostate-specific antigen (PSA) and digital rectal examination in men (aged 40-49 years) in predicting long-term prostate cancer risk in a prospectively followed, representative population cohort. PATIENTS AND METHODS: Since 1990, a random sample of men in Olmsted County (aged 40-49 years) has been followed up prospectively (n = 268), with biennial visits, including a urologic
“The dairy story can be confusing,” says June Chan, professor of epidemiology & biostatistics and urology at the University of California, San Francisco. She and others followed nearly 4,000 health professionals with localized prostate cancer for eight years to see which men were more likely to “progress.” Read the article.
Men with prostate cancer who ate a low-fat diet and took fish oil supplements had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score, a measure used to predict cancer recurrence, than men who ate a typical Western diet, UCLA researchers found. The findings are important because lowering the cell cycle progression (CCP) score may help prevent prostate cancers from becoming more aggressive, said study lead author William Aronson, a clinical professor of urology at UCLA and chief of urologic oncology at the West Los Angeles Veterans Affairs Medical Center. Read the article.
A study that you probably won’t be reading in your daily paper or favourite news website anytime soon casts serious doubts on the reliability of mainstream medical and health journalism. The study found that 51% of news items reporting on medical trials – specifically on randomised controlled trials (RCTs), which are seen as the gold standard in judging whether a treatment is effective or safe – were subject to “spin”. Read the article.
New prostate test that identifies less harmful tumours that do not need to be removed immediately will spare men from needless surgery
A new test for prostate cancer could spare thousands of men needless treatment which leaves them with debilitating side effects, researchers claim. The test can accurately pinpoint the less harmful tumours which do not have to be immediately removed by surgery or radiotherapy. Read more: http://www.dailymail.co.uk/health/article-2487483/New-prostate-test-identifies-harmful-tumours-need-removed-immediately-spare-men-needless-surgery.html#ixzz2lIfSTsd7
Abstract For many years, few therapeutic options were available for the treatment of advanced prostate cancer. Recent advances in our understanding of the molecular biology of prostate cancer, particularly in the transition to castrate resistant disease, have led to the development of more potent and selective endocrine therapies. In addition, elucidation of the many factors in the bone microenvironment that promote the development and subsequent progression of skeletal metastases has led to the discovery of new bone-targeting agents that can delay the onset of skeletal related events and improve quality of life and survival. This review will highlight recently approved